by Riley Nolan | Jul 6, 2021 | Featured, News
PROVIDENCE, RI, July 6, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce that Dr. Amy Rosenberg is leaving the FDA’s Division of Therapeutic Proteins, CDER, which she led for over 20 years, to join EpiVax as Senior Director of Immunology and...
by Admin Epivax | Aug 22, 2017 | EpiVax Immunoncology, Featured, News, Thinking Out Loud -Blog
EpiVax has carved out a niche in the biotech and immunoinformatics industry with our innovative tools and discoveries. Well-situated on a trajectory Dr. De Groot described as “upward and stable,” EpiVax is now gearing up to launch a venture-backed spinoff called...
by Admin Epivax | Aug 3, 2017 | EpiVax Immunoncology, News, Thinking Out Loud -Blog
Accelerating the Development of a Game Changing Cancer Therapy PROVIDENCE, R.I., Aug. 3, 2017 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) today announced it received funding from the Rhode Island Commerce Corporation to accelerate the development of...
by Annie De Groot | Jan 2, 2017 | EpiVax Immunoncology, News, Thinking Out Loud -Blog
EpiVax Oncology – New Year, New Endeavor! A nice story in ConvergenceRI that describes the rapid growth of EpiVax and our decision to invest in a new spin-out company in 2017: Welcome EpiVax Oncology! Annie was interviewed by Richard Asinof about “EpiVax...
by Admin Epivax | Dec 8, 2016 | Events, Featured, News, Thinking Out Loud -Blog
EpiVax will be joining more than 1,400 companies from over 45 countries at Bio-Europe Spring, the premier springtime partnering conference bringing together a “whoʼs who” from biotech, pharma and finance in Europe’s most innovative biopharma clusters. Partner...
